Advertisement
Table 2 Correlation between mutational status and resistance to anti-EGFR moAb therapy
| Mutant genes | Responders (CR + PR + SD)a vs non-responders | ||||
|---|---|---|---|---|---|
| Total responders | Total non-responders | Mutant responders | Mutant non-responders | P-valueb | |
| KRAS c | 37 | 28 | 3 | 8 | 0.045 |
| NRAS | 37 | 28 | 1 | 1 | 0.999 |
| BRAF | 37 | 28 | 1 | 4 | 0.156 |
| PI3KCA | 37 | 28 | 2 | 4 | 0.389 |
| FBXW7 | 37 | 28 | 1 | 5 | 0.077 |
| SMAD4 | 37 | 28 | 1 | 4 | 0.156 |
| NRAS/BRAF/PIK3CA d | 37 | 28 | 3 | 8 | 0.045 |
| NRAS/BRAF/PIK3CA/FBXW7 d | 37 | 28 | 4 | 11 | 0.016 |
| NRAS/BRAF/PIK3CA/FBXW7/SMAD4 d | 37 | 28 | 4 | 13 | 0.002 |
